2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.03 Potugari

PP01.03 Potugari - Abstract

Pdf Summary

A study conducted at the Henry Ford Health System involving 277 patients diagnosed with small-cell lung cancer (SCLC) between 2018 and 2023 focused on the outcomes of patients with primary tumor sizes of 2cm or less compared to larger tumors. The majority of patients were Caucasian, former smokers, and females. The analysis revealed that patients with tumors larger than 2cm were more likely to have extensive-stage SCLC compared to those with smaller tumors. Patients with tumors 2cm or less had a median overall survival of 20 months versus 9.7 months for those with larger tumors, and a median progression-free survival of 12.6 months versus 8 months. Extensive-stage disease was associated with worse overall and progression-free survival regardless of tumor size. Limited-stage patients were more prevalent among those with smaller tumors. The presence of brain metastasis at diagnosis did not show a significant association with survival outcomes. Overall, the study suggests that patients with SCLC and primary tumors 2cm or less had outcomes in line with expected survival based on disease stage.

Keywords

Henry Ford Health System

small-cell lung cancer

SCLC

tumor size

Caucasian

former smokers

females

overall survival

progression-free survival

brain metastasis